PaulJ.ShamiMD
Hematology • Salt Lake City, UTHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Professor, Internal Medicine, University of Utah School of Medicine
Dr. Shami is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1950 Circle of Hope Dr
Salt Lake City, UT 84112Phone+1 801-581-2121
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994- Duke University HospitalResidency, Internal Medicine, 1988 - 1991
American University of Beirut Faculty of MedicineClass of 1988
Certifications & Licensure
UT State Medical License 1997 - 2026
NC State Medical License 1991 - 1999
MD State Medical License 1990 - 1991- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Start of enrollment: 2008 Mar 01
- Decitabine Maintenance in Elderly Acute Myeloid Leukemia Patients Start of enrollment: 2011 Feb 01
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Join now to see all
Publications & Presentations
PubMed
- 26 citationsREVEAL‐1, a phase 2 dose regimen optimization study of vosaroxin in older poor‐risk patients with previously untreated acute myeloid leukaemiaRobert K. Stuart, Larry D. Cripe, Michael B. Maris, Maureen A. Cooper, Richard Stone
British Journal of Haematology. 2015-03-01 - 69 citationsPhase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemiaHarry P. Erba, Pamela S. Becker, Paul J. Shami, Michael R. Grunwald, Donna L. Flesher
Blood Advances. 2019-07-09 - 459 citationsThe price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML expertsCamille N. Abboud, Ellin Berman, Adam D. Cohen, Jorge E. Cortes, Daniel J. DeAngelo
Blood. 2013-05-30
Abstracts/Posters
- Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master TrialPaul J Shami, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Durham’s Chimerix Pays $30M to Secure Rights for Late-Stage Leukemia DrugAugust 2nd, 2019
Chimerix Announces Exclusive Worldwide License of Phase 3 Ready CX-01 for Development in Acute Myeloid LeukemiaJuly 31st, 2019
Huntsman Cancer Institute Joins Study Aimed at Improving Leukemia Screening, TreatmentMarch 19th, 2018- Join now to see all
Grant Support
- Preclinical Development Of JS-K, A Novel No-Generating Prodrug For CancerNational Cancer Institute2010–2012
- Development Of JS-K As An Anti-Leukemic AgentNational Cancer Institute2008–2012
- Role Of Nitric Oxide In Myelodysplastic SyndromesNational Center For Research Resources2005
- Genetic Targets Of Nitric Oxide In Leukemia CellsNational Cancer Institute2002–2004
- NO, Guanylate Cyclase And Immunotherapy Of CancerNational Cancer Institute2000
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
